Using an established preclinical model of psoriasis, we demonstrate that VEGF‐A inhibition alters the transcription of genes involved in lipid metabolism and that the interferon (IFN) family mediate these effects in non‐lesional skin from patients with psoriasis. The gene discussed is VEGFA; the disease is psoriasis.